# Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

> **NCT05901545** · PHASE1 · RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Panitumumab
- **OTHER:** Indium In 111 Panitumumab
- **PROCEDURE:** Single Photon Emission Computed Tomography
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Surgical Procedure
- **OTHER:** Imaging agent
- **PROCEDURE:** Intraoperative Imaging
- **PROCEDURE:** Near Infrared Imaging
- **PROCEDURE:** Electrocardiography
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT05901545
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-22
- **Primary completion:** 2028-11-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05901545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05901545, "Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05901545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*